Form 4: Arbutus Biopharma Director Acquires Stock Options

James R. Meyers, a director of Arbutus Biopharma Corp, acquired stock options for 67,000 common shares on May 23, 2024.

Summary

• On May 23, 2024, James R. Meyers, a director of Arbutus Biopharma Corp, was granted stock options to purchase 67,000 common shares.
• The exercise price of these options is $3.28 per share.
• The options are fully vested and exercisable as of the grant date.
• The options expire on May 23, 2034.
• This transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock option grants. It doesn't contain overtly positive or negative information, but the granting of options can be seen as a mild positive, indicating alignment of interests.

Positives

• The director's acquisition of stock options could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning the interests of management and shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates